The polymorphic variants DRD2, DRD3, and DRD4 are associated with early efficacy and safety of antipsychotics in adolescents with an acute psychotic episode
D. V. Ivaschenko, L. Fedina, D.A. Yudelievich, N. Buromskaya, P. V. Shimanov, R. V. Deitsch, I. V. Dorina, K. Akmalova, A. Kachanova, E. Grishina, L. Savchenko, Y. Shevchenko, D. Sychev
{"title":"The polymorphic variants DRD2, DRD3, and DRD4 are associated with early efficacy and safety of antipsychotics in adolescents with an acute psychotic episode","authors":"D. V. Ivaschenko, L. Fedina, D.A. Yudelievich, N. Buromskaya, P. V. Shimanov, R. V. Deitsch, I. V. Dorina, K. Akmalova, A. Kachanova, E. Grishina, L. Savchenko, Y. Shevchenko, D. Sychev","doi":"10.32756/0869-5490-2021-2-75-80","DOIUrl":null,"url":null,"abstract":"The prospective observational study included 101 adolescents diagnosed with acute polymorphic psychotic disorder at the time of admission. Patients were followed up for 14 days. All patients received an antipsychotic as their main therapy. The following scales were used to assess the efficacy and safety of therapy on day 14: CGAS, PANSS, CGI-S, CGI-I, UKU SERS, SAS, BARS. The determination of polymorphic variants of DRD2 (rs1800497, C>T), DRD3 (rs6280, C>T), DRD3 (rs324026, C>T), and DRD4 (rs1800955, C>T) genes was performed by real-time polymerase chain reaction (PCR).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"236 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2021-2-75-80","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
The prospective observational study included 101 adolescents diagnosed with acute polymorphic psychotic disorder at the time of admission. Patients were followed up for 14 days. All patients received an antipsychotic as their main therapy. The following scales were used to assess the efficacy and safety of therapy on day 14: CGAS, PANSS, CGI-S, CGI-I, UKU SERS, SAS, BARS. The determination of polymorphic variants of DRD2 (rs1800497, C>T), DRD3 (rs6280, C>T), DRD3 (rs324026, C>T), and DRD4 (rs1800955, C>T) genes was performed by real-time polymerase chain reaction (PCR).
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
